Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amphastar Pharmaceuticals Inc (AMPH) vs Vital Farms Inc (VITL) Price & Performance

Amphastar Pharmaceuticals IncTrade
Vital Farms IncTrade

Price performance (Past 24H)

Key statistics

Amphastar Pharmaceuticals Inc vs Vital Farms Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Vital Farms Inc trades at $11.57 (market cap $483.84M). The key difference: Amphastar Pharmaceuticals Inc is the larger of the two by market cap, and Amphastar Pharmaceuticals Inc is trading nearer its 52-week high, Vital Farms Inc nearer its low. Which is the better fit depends on your goals.

AMPHVITL
Market Cap
$863.95M$483.84M
Sector
HealthConsumer Staples
52-Week High
$30.81$52.41
52-Week Low
$16.87$8.28
Enterprise Value
$1.26B$570.85M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amphastar Pharmaceuticals Inc

AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.

Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.

Vital Farms Inc

Vital Farms (VITL) trades at $12.24, down 2.16% amid bearish technical signals and challenging Q2 2026 results with a net loss of $0.47 per share. Revenue declined 10.1% year-over-year to $166 million due to industry oversupply and competitive pressures. The company secured $125 million in term loan financing in August 2026 to support operations. Analyst consensus remains positive with a $13.00 price target and 56% buy ratings, though profitability metrics show significant compression with net income margin at 0.02%.

The stock faces near-term headwinds from operational challenges but maintains analyst support. Investment opportunity exists if the company can navigate industry oversupply and restore profitability. Key risks include persistent margin pressure, competitive pricing gaps, and execution of the new financing strategy. The current valuation at 11.77 P/E appears reasonable if earnings recovery materializes.

Returns comparison

Trailing returns across standard periods

About Amphastar Pharmaceuticals Inc

Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.

Read more on AMPH

About Vital Farms Inc

Vital Farms is a leading provider of ethically produced, pasture-raised eggs and butter in the United States. Operating as a Public Benefit Corporation, it manages a network of over 650 family farms to deliver high-welfare food products. It leverages a scalable 'asset-light' partnership model that prioritizes transparency and animal welfare to meet the growing consumer demand for clean-label and sustainable food sources.

Read more on VITL